First Patient dosed in the RIVER-52 Ph 2 Study of RVU120 for the Treatment of Patients with R/R AML and HR-MDS February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML) February 26, 2024
Final Results of Ph 3 ASCERTAIN Trial of Oral Decitabine and Cedazuridine Fixed Dose Combination (INQOVI®) in Patients With MDS and CMML published February 16, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
Complete Remission Of The Cohort 1 First Patient Treated For R/R B-ALL In Ph 1 Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 31, 2024
BLA accepted for obecabtagene autoleucel (obe-cel) as a potential treatment for R/R Adult B-cell ALL January 31, 2024
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) January 23, 2024
First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed January 18, 2024
Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML January 10, 2024
Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed January 10, 2024
Scemblix Shows Superior MMR Rates Vs. SoC TKIs In Ph 3 Trial For Newly Diagnosed Patients With CML January 10, 2024
FDA Clears IND Application for SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML January 4, 2024
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
US FDA Accepts for Priority Review Application for Breyanzi (lisocabtagene maraleucel) for R/R CLL/SLL December 4, 2023
